Form 4: BioXcel CSO Converts RSUs to Common Stock

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, converted a total of 68 Restricted Stock Units into common stock on September 14 and 15, 2025.

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. (BTAI), reported transactions involving company stock.
• On September 14, 2025, 33 Restricted Stock Units (RSUs) were converted into 33 shares of common stock.
• On September 15, 2025, an additional 35 RSUs were converted into 35 shares of common stock.
• Following these transactions, Yocca directly beneficially owns 6,384 shares of common stock and 317 Restricted Stock Units.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The conversions relate to RSU grants from March 14, 2022 (521 RSUs) and March 15, 2023 (562 RSUs), which vest over time subject to continuous employment.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, which is a neutral event in terms of company performance or outlook. It does not introduce new positive or negative information.

Positives

• The Chief Scientific Officer's conversion of RSUs into common stock increases his direct ownership in the company, aligning his interests with those of shareholders.
• The transactions are part of a pre-existing, routine compensation plan, indicating stability in executive incentives.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction related to executive compensation, which is a standard practice across publicly traded companies. It does not provide information relevant to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock results in a minor, expected increase in the outstanding share count, while also reinforcing the alignment of executive interests with shareholder value.
• Employees: The filing reflects standard executive compensation practices, which can serve as a benchmark for equity incentive programs within the company.

Next Steps

• Continued vesting of the remaining Restricted Stock Units held by the Reporting Person, subject to continuous employment.

Key Dates

Recommendation

This Form 4 reports routine vesting and conversion of Restricted Stock Units (RSUs) by a key executive. It does not contain any new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The transactions are part of a pre-existing compensation plan and are expected.

Keywords

BioXcel Therapeutics, BTAI, Frank Yocca, Chief Scientific Officer, Form 4, SEC filing, insider transaction, RSU conversion, common stock, beneficial ownership